Kidney cancer drugs market

Kidney Cancer Drugs Market, by Therapy (Targeted Therapy, Immunotherapy and Chemotherapy), by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, Antimetabolites and Others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2022
CMI2399
173 Pages
Excel & Pdf
Pharmaceutical

Summary

Kidney cancer is a cancer that begins in the cells of kidneys. Kidney cancer is a cancer that begins in the kidneys. Kidneys are two bean-shaped organs, each about the size of fist. They're located behind abdominal organs, with one kidney on each side of spine. Renal cell carcinoma (RCC) is one of the most common types of kidney cancer in adults. At the advanced progression stage of kidney cancer, where removal of the cancerous cells is vital, surgical removal of kidney is performed to get cure from the disease. This treatment method has been replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

Global kidney cancer drugs market is estimated to be valued at US$ 5.83 billion in 2022 and is expected to exhibit a CAGR of 6.4% during the forecast period (2022-2030).

Figure 1. Global Kidney Cancer Drugs Market Share (%), by Pharmacologic Class, 2022

Increased prevalence of renal cell carcinoma is expected to drive the adoption of kidney cancer drugs during the forecast period.

Increasing prevalence of renal cell carcinoma is expected to drive the global kidney cancer drugs market over the forecast period. For instance, in February 2022, American Society of Clinical Oncology (ASCO), in 2022, an estimated 79,000 adults (50,290 men and 28,710 women) in the U.S. would be diagnosed with kidney cancer. Worldwide, an estimated 431,288 people were diagnosed with kidney cancer in 2020. In the U.S., kidney cancer is the sixth most common cancer for men. It is the ninth most common cancer for women. The average age at diagnosis for people with kidney cancer is 64, and most people are diagnosed between the ages of 65 and 74. Renal cell carcinoma (RCC) accounts for approximately 4% of all adult malignancies with nearly 270,000 new cases diagnosed annually worldwide in 2018 according to the National Center for Biotechnology Information.

Kidney Cancer Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 5.83 Bn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	6.4%	2030 Value Projection:	US$ 9.60 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
Growth Drivers:	Increased prevalence of renal cell carcinoma Combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer
Restraints & Challenges:	Increasing use of targeted therapies and biologics for the treatment of kidney cancer

Figure 2. Global Kidney Cancer Drugs Market Share (%), by Region, 2022

Combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer, which offer lucrative growth opportunities for the market over the forecast period.

In recent times, combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer, which offer lucrative growth opportunities for the market over the forecast period. For instance, in December 2017, the U.S. Food and Drug administration granted Breakthrough Therapy designation to avelumab, PD-L1 immune checkpoint inhibitor, and axitinib, anti-VEGF tyrosine kinase inhibitor (TKI), as a combination therapy for treatment-naive patients with advanced Renal Cell Carcinoma. Furthermore, in January 2018, U.S. Food and Drug administration granted the same designation to, lenvatinib mesylate, multi-TKI, and pembrolizumab, PD-1 immune checkpoint inhibitor, as another combination for mRCC. Moreover, the field of initial treatment therapy for metastatic renal cell carcinoma is moving rapidly towards combination therapy.

Global Kidney Cancer Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global kidney cancer drugs market, owing to the decrease in research and development activities for kidney cancer drugs. For instance, in May 2020, according to data published by the National Center for Biotechnology Information, the clinicians were focused on developing the SARS-CoV-2 vaccine to prevent the rapid spread of the coronavirus in the world. The coronavirus disease 2019 (COVID-19) was spreading globally at an alarming rate due to which government of countries announced lockdown all over the world. Capacity for surgery has also been reduced as theater space and ventilators have been requisitioned to provide additional critical care capacity for patients with COVID-19. Moreover, anecdotal reports of patients developing COVID-19 after admission to hospital for elective surgery had resulted in patients being more reluctant to have surgery. Thus, as large number of researchers and clinicians were concentrated on developing covid-19 vaccine, the research and development activities for the kidney cancer drugs were decreased.

Global Kidney Cancer Drugs Market: Key Developments

In January 2022, Clinical Hospital of the Faculty of Medicine of Ribeirão Preto collaborated with Bristol Myers Squibb (pharmaceutical company) and São Paulo Research Foundation for developing Nivolumab- new drug on renal cancer. Nivolumab is in the Phase 2 clinical trial whose study was started in January 18 2022. The primary completion date is estimated to be November 30, 2024.

Global Kidney Cancer Drugs Market: Restraint

The major factors that hinder growth of the global kidney cancer drugs market include increasing use of targeted therapies and biologics for treatment of kidney cancer. Targeted therapies are used to control cancer cell when kidney cancer is spread to other organs where chemical drugs are ineffective. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials.

Key Players

Major players operating in the global kidney cancer drugs market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.

Table of Content

Table of Contents

*Browse 25 market data tables and 29 figures on "Global Kidney Cancer Drugs Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global kidney cancer drugs market during the forecast period (2022-2030)?

The global kidney cancer drugs market size is estimated to be valued at US$ 5.83 billion in 2022 and is expected to exhibit a CAGR of 6.4% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increased prevalence of renal cell carcinoma and combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer are expected to drive the market growth.

Which is the leading pharmacologic class segment in the market?

Angiogenesis inhibitors is the leading pharmacologic class segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include increasing use of targeted therapies and biologics for treatment of kidney cancer.

Which are the major players operating in the market?

Major players operating in the market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.